FY2027 Earnings Estimate for ESPR Issued By Zacks Research

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Investment analysts at Zacks Research cut their FY2027 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued on Thursday, July 10th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings per share of $0.06 for the year, down from their previous forecast of $0.09. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share.

A number of other equities analysts have also recently commented on the stock. The Goldman Sachs Group dropped their price target on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Needham & Company LLC lowered their target price on Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, HC Wainwright reissued a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Tuesday, June 17th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $7.00.

Esperion Therapeutics Price Performance

Shares of Esperion Therapeutics stock traded down $0.01 on Friday, reaching $1.18. The company had a trading volume of 1,416,587 shares, compared to its average volume of 4,607,026. The firm's 50-day moving average price is $1.01 and its two-hundred day moving average price is $1.42. The firm has a market cap of $233.88 million, a price-to-earnings ratio of -1.47 and a beta of 0.70. Esperion Therapeutics has a 1 year low of $0.69 and a 1 year high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). The business had revenue of $65.00 million for the quarter, compared to the consensus estimate of $54.97 million. Esperion Therapeutics had a negative net margin of 59.03% and a negative return on equity of 0.91%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Sivia Capital Partners LLC acquired a new stake in Esperion Therapeutics during the second quarter worth about $25,000. Meridian Wealth Management LLC acquired a new position in shares of Esperion Therapeutics in the 1st quarter worth approximately $29,000. Cibc World Markets Corp purchased a new position in shares of Esperion Therapeutics during the fourth quarter worth $39,000. Synergy Asset Management LLC boosted its stake in shares of Esperion Therapeutics by 3,496.3% in the first quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 30,138 shares during the period. Finally, Private Advisor Group LLC grew its stake in shares of Esperion Therapeutics by 33.2% in the first quarter. Private Advisor Group LLC now owns 40,106 shares of the biopharmaceutical company's stock worth $58,000 after acquiring an additional 10,000 shares in the last quarter. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.